Figure 3

Expression of cell viability (A) and HCV genome replication (B) in hepatocytes treated with different biologics. Tofa, tofacitinib; RTX, rituximab; ADA, adalimumab; ETA, etanercept; GOL, golimumab; HCV, hepatitis C virus; DMSO, 2% dimethyl sulfoxide. All experiments were performed in triplicate, and data are presented as the mean ± SD.